Evidence map›Paper›PMID 36523928›Full record

ArticleHepatobiliary surgery and nutrition2022

Propensity score matching study of 325 patients with spontaneous rupture of hepatocellular carcinoma.

Wei Wang, Tao Meng, Ying Chen, Ye-Chuan Xu, Yi-Jun Zhao, Yan Zhang, Ming-Ya Yang, Zhi-Hua Zhang, Fan Huang, Hong-Chuan Zhao and 2 more

Abstract read
In one paragraph

Article in Hepatobiliary surgery and nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Meta-analysis of Prognostic Factors for Overall Survival Among Resected Patients with Spontaneous Ruptured Hepatocellular Carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Pooled it
  2. Article
  3. Primary hepatic pleomorphic liposarcoma with rupture.Clinical journal of gastroenterology · 2026
    Article
  4. Article
  5. Article
  6. Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Observational
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Revision and addendum to the manuscript titled "Hepatobiliary surgery and nutrition · 2023
    Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Wei Wang *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Tao Meng *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ying Chen *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ye-Chuan Xu *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yi-Jun Zhao *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yan Zhang *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ming-Ya Yang *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Zhi-Hua Zhang *Department of Statistics, Anhui Medical University, Hefei, China.
Fan Huang *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hong-Chuan Zhao *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xiao-Ping Geng *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Li-Xin ZhuDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aims to find out the possible optimal therapy and assess the prognosis properly for patient with spontaneous rupture of hepatocellular carcinoma (HCC). Methods: Propensity score matching (PSM) analysis was used to study the data from 325 patients with ruptured HCC (RHCC) and 2,291 patients with non-RHCC. Results: The incidence and hospital mortality of RHCC were 5.1% and 0.8% respectively, with a median overall survival (OS) time of 17 months. There was no difference between ruptured and non-RHCC patients undergoing conservation treatment in terms of OS. Trans-arterial embolization (TAE) was carried out in 69 (21.2%) cases with RHCC, with a median OS of 7 months, which was no difference from that of non-RHCC (pre- and post-PSM). One hundred and sixty-nine (52.0%) RHCC cases underwent one-stage hepatectomy, with a median OS and disease-free survival (DFS) of 30 and 6 months respectively, which were shorter than that of non-RHCC (post-PSM). TAE plus two-stage hepatectomy was performed in 30 RHCC cases, with a median OS and DFS of 28 and 10 months respectively; these outcomes were better than that from RHCC patients undergoing TAE alone or one-stage hepatectomy (post-PSM), which were no difference from that of non-RHCC patients undergoing hepatectomy. The risk of death for RHCC patient undergoing one-stage hepatectomy is 1.545 times higher than that of one undergoing TAE + two-stage hepatectomy. Conclusions: TAE plus two-stage hepatectomy might be the optimal treatment for RHCC patient. Under the premise of the same pathological properties, there is no difference in prognosis between ruptured and non-RHCC patients if the therapy is appropriate.

Indexed as

conservative treatmenthepatectomyHepatocellular carcinoma (HCC)prognosisrupturetrans-arterial embolization (TAE)

Identifiers

PMID36523928
PMCPMC9745608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.